Signaturefd LLC Sells 302 Shares of Revvity Inc. $RVTY

Signaturefd LLC lowered its stake in shares of Revvity Inc. (NYSE:RVTY) by 16.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,528 shares of the company’s stock after selling 302 shares during the quarter. Signaturefd LLC’s holdings in Revvity were worth $148,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. boosted its holdings in Revvity by 8.5% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 22,515,711 shares of the company’s stock valued at $2,382,163,000 after acquiring an additional 1,754,403 shares during the period. Vanguard Group Inc. boosted its holdings in Revvity by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 14,382,849 shares of the company’s stock valued at $1,521,705,000 after acquiring an additional 92,638 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Revvity by 25.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,563,911 shares of the company’s stock valued at $1,011,863,000 after acquiring an additional 1,932,314 shares during the period. EdgePoint Investment Group Inc. boosted its holdings in Revvity by 32.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 5,360,847 shares of the company’s stock valued at $567,178,000 after acquiring an additional 1,302,616 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Revvity by 1.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,444,645 shares of the company’s stock valued at $364,443,000 after acquiring an additional 62,307 shares during the period. Institutional investors own 86.65% of the company’s stock.

Revvity Trading Up 3.0%

Shares of NYSE:RVTY opened at $94.17 on Friday. The business’s 50-day moving average is $88.08 and its 200 day moving average is $93.51. Revvity Inc. has a 1 year low of $81.36 and a 1 year high of $129.50. The firm has a market capitalization of $10.93 billion, a P/E ratio of 39.90, a P/E/G ratio of 3.05 and a beta of 0.98. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.33 and a quick ratio of 2.75.

Revvity (NYSE:RVTY) last announced its earnings results on Monday, July 28th. The company reported $1.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.04. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The company had revenue of $720.28 million for the quarter, compared to analyst estimates of $711.26 million. During the same period in the prior year, the company posted $1.22 EPS. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. On average, research analysts predict that Revvity Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 17th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Friday, October 17th. Revvity’s dividend payout ratio is currently 11.86%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Bank of America dropped their price objective on Revvity from $110.00 to $99.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Barclays dropped their price objective on Revvity from $110.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday. Evercore ISI lowered their target price on Revvity from $116.00 to $115.00 and set an “outperform” rating for the company in a report on Tuesday, July 8th. Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 3rd. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $115.00 target price (down from $120.00) on shares of Revvity in a report on Tuesday, July 29th. Ten investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Revvity presently has an average rating of “Moderate Buy” and an average target price of $118.57.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.